Achieving zero asthma-related hospitalisations in the world´s first SABA-free Asthma Center in Argentina.
Saved in:
| Title: | Achieving zero asthma-related hospitalisations in the world´s first SABA-free Asthma Center in Argentina. |
|---|---|
| Authors: | Nannini, Luis J. (AUTHOR), Brandan, Nadia (AUTHOR), Fernandez, Octavio M. (AUTHOR) |
| Source: | Journal of Asthma. Jun2023, Vol. 60 Issue 6, p1057-1060. 4p. |
| Subjects: | Asthma, Medical personnel, Wheeze |
| Abstract: | Apart from asthma studies that used anti-inflammatory reliever therapy, all trials used SABA as a reliever therapy with higher patient adherence to maintenance therapy than observed in real-world clinical practice. I To the Editor i , The Global Initiative for Asthma (GINA) 2021 strategy report no longer recommends short-acting SB 2 sb -agonists (SABAs) as the preferred reliever therapy without concomitant inhaled corticosteroid (ICS) therapy ([1]). We implemented a multi-pronged strategy, targeting both patients and healthcare providers (Figure 1), which helped achieve our "asthma-zero" goal in >600 patients with asthma in our center, i.e. no recorded asthma hospitalizations and ER visits ([14]). Finally, a systematic review and meta-analysis found that ICS therapy reduces hospital admissions in patients with acute asthma, but there is insufficient evidence that ICS therapy can be used in place of systemic corticosteroid therapy when treating acute asthma ([18]). [Extracted from the article] |
| Copyright of Journal of Asthma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Apart from asthma studies that used anti-inflammatory reliever therapy, all trials used SABA as a reliever therapy with higher patient adherence to maintenance therapy than observed in real-world clinical practice. I To the Editor i , The Global Initiative for Asthma (GINA) 2021 strategy report no longer recommends short-acting SB 2 sb -agonists (SABAs) as the preferred reliever therapy without concomitant inhaled corticosteroid (ICS) therapy ([1]). We implemented a multi-pronged strategy, targeting both patients and healthcare providers (Figure 1), which helped achieve our "asthma-zero" goal in >600 patients with asthma in our center, i.e. no recorded asthma hospitalizations and ER visits ([14]). Finally, a systematic review and meta-analysis found that ICS therapy reduces hospital admissions in patients with acute asthma, but there is insufficient evidence that ICS therapy can be used in place of systemic corticosteroid therapy when treating acute asthma ([18]). [Extracted from the article] |
|---|---|
| ISSN: | 02770903 |
| DOI: | 10.1080/02770903.2022.2137036 |
